Establishment of a cell-based assay for screening of compounds inhibiting very early events in the cytomegalovirus replication cycle and characterization of a compound identified using the assay

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 7, 2008, Pages 2420-2427

  Fukui, Yoshiko ^a   Shindoh, Keiko ^a,b   Yamamoto, Yumiko ^a   Koyano, Shin ^c   Kosugi, Isao ^d   Yamaguchi, Toyofumi ^b   Kurane, Ichiro ^a   Inoue, Naoki ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b TEIKYO UNIVERSITY OF SCIENCE   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

^d HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,5 DICHLORO 4 PYRIDYL)PIPERIDINE 4 CARBOXAMIDE; ANTIVIRUS AGENT; DERMATAN SULFATE; GANCICLOVIR; HEPARAN SULFATE; IMMEDIATE EARLY PROTEIN; LUCIFERASE; MESSENGER RNA; ROSCOVITINE; SURAMIN; VIRUS DNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL STRAIN 3T3; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPLICATION; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; LUNG FIBROBLAST; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VERO CELL; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CYTOMEGALOVIRUS; DNA REPLICATION; GENES, IMMEDIATE-EARLY; GUINEA PIGS; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; MUROMEGALOVIRUS; PIPERIDINES; PLAQUE ASSAY; RNA, MESSENGER; RNA, VIRAL; ROSEOLOVIRUS; VIRUS REPLICATION;

EID: 46249110369     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00134-08     Document Type: Article

References (48)

1. Alexander, R., D. Lamb, D. White, T. Wentzel, S. Politis, J. Rijnsburger, D. van Ruyven, N. Kelly, and S. M. Garland. 2001. 'RETCIF': a rapid, sensitive method for detection of viruses, applicable for large numbers of clinical samples. J. Virol. Methods 97:77-85.
2. Baba, M., K. Konno, S. Shigeta, A. Wickramasinghe, and P. Mohan. 1993. Selective inhibition of human cytomegalovirus replication by naphthalenedisulfonic acid derivatives. Antiviral Res. 20:223-233.
3. Barbi, M., S. Binda, V. Primache, S. Caroppo, P. Didò, P. Guidotti, C. Corbetta, and D. Melotti. 2000. Cytomegalovirus DNA detection in Guthrie cards: a powerful tool for diagnosing congenital infection. J. Clin. Virol. 17:159-165.
4. Bechtel, J. T., and T. Shenk. 2002. Human cytomegalovirus UL47 tegument protein functions after entry and before immediate-early gene expression. J. Virol. 76:1043-1050.
5. Bedard, J., S. May, D. Barbeau, L. Yuen, R. F. Rando, and T. L. Bowlin. 1999. A high throughput colorimetric cell proliferation assay for the identification of human cytomegalovirus inhibitors. Antivir. Res. 41:35-43.
6. Biron, K. K. 2006. Antiviral drugs for cytomegalovirus diseases. Antivir. Res. 71:154-163.
7. Black, D. H., J. T. Saliki, and R. Eberle. 2002. Development of a green fluorescent protein reporter cell line to reduce biohazards associated with detection of infectious Cercopithecine herpesvirus 1 (monkey B virus) in clinical specimens. Comp. Med. 52:534-542.
8. Chambers, J., A. Angulo, D. Amaratunga, H. Guo, Y. Jiang, J. S. Wan, A. Bittner, K. Frueh, M. R. Jackson, P. A. Peterson, M. G. Erlander, and P. Ghazal. 1999. DNA microarrays of the complex human cytomegalovirus genome: profiling kinetic class with drug sensitivity of viral gene expression. J. Virol. 73:5757-5766.
9. Chee, M. S., A. T. Bankier, S. Beck, R. Bohni, C. M. Brown, R. Cerny, T. Horsnell, C. A. Hutchison III, T. Kouzarides, J. A. Martignetti, et al. 1990. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr. Top. Microbiol. Immunol. 154:125-169.
10. Chou, S., and C. L. Meichsner. 2000. A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir. Antimicrob. Agents Chemother. 44:183-185.
11. De Clercq, E. 2003. New inhibitors of human cytomegalovirus (HCMV) on the horizon. J. Antimicrob. Chemother. 51:1079-1083.
12. Feng, X., J. Schröer, D. Yu, and T. Shenk. 2006. Human cytomegalovirus pUS24 is a virion protein that functions very early in the replication cycle. J. Virol. 80:8371-8378.
13. Gilbert, C., and G. Boivin. 2005. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure. Antimicrob. Agents Chemother. 49:4860-4866.
14. Grose, C., and P. A. Brunel. 1978. Varicella-zoster virus: isolation and propagation in human melanoma cells at 36 and 32 degrees C. Infect. Immun. 19:199-203.
15. Hudson, J. B. 1988. Further studies on the mechanism of centrifugal enhancement of cytomegalovirus infectivity. J. Virol. Methods 19:97-108.
16. Inoue, N., T. R. Dambaugh, J. C. Rapp, and P. E. Pellett. 1994. Alphaherpesvirus origin-binding protein homolog encoded by human herpesvirus 6B, a betaherpesvirus, binds to nucleotide sequences that are similar to ori regions of alphaherpesviruses. J. Virol. 68:4126-4136.
17. Inoue, N., J. Winter, R. B. Lal, M. K. Offermann, and S. Koyano. 2003. Characterization of entry mechanisms of human herpesvirus 8 by using an Rta-dependent reporter cell line. J. Virol. 77:8147-8152.
18. Jones, T. R., S. W. Lee, S. V. Johann, V. Razinkov, R. J. Visalli, B. Feld, J. D. Bloom, and J. O'Connell. 2004. Specific inhibition of human cytomegalovirus glycoprotein B-mediated fusion by a novel thiourea small molecule. J. Virol. 78:1289-1300.
19. Jordan, R., L. Schang, and P. A. Schaffer. 1999. Transactivation of herpes simplex virus type 1 immediate-early gene expression by virion-associated factors is blocked by an inhibitor of cyclin-dependent protein kinases. J. Virol. 73:8843-8847.
20. Katano, H., Y. Sato, Y. Tsutsui, T. Sata, A. Maeda, N. Nozawa, N. Inoue, Y. Nomura, and T. Kurata. 2007. Pathogenesis of cytomegalovirus- associated labyrinthitis in a guinea pig model. Microbes Infect. 9:183-191.
21. Kimberlin, D. W., C. Y. Lin, P. J. Sánchez, G. J. Demmler, W. Dankner, M. Shelton, R. F. Jacobs, W. Vaudry, R. F. Pass, J. M. Kiell, S. J. Soong, and R. J. Whitley. 2003. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J. Pediatr. 143:16-25.
22. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66:2232-2239.
23. Klucher, K. M., D. K. Rabert, and D. H. Spector. 1989. Sequences in the human cytomegalovirus 2.7-kilobase RNA promoter which mediate its regulation as an early gene. J. Virol. 63:5334-5343.
24. Koyano, S., E. C. Mar, F. R. Stamey, and N. Inoue. 2003. Glycoproteins M and N of human herpesvirus 8 form a complex and inhibit cell fusion. J. Gen. Virol. 84:1485-1491.
25. Krug, L. T., V. P. Pozharskaya, Y. Yu, N. Inoue, and M. K. Offermann. 2004. Inhibition of infection and replication of human herpesvirus 8 in microvascular endothelial cells by alpha interferon and phosphonoformic acid. J. Virol. 78:8359-8371.
26. Kucić, N., H. Mahmutefendić, and P. Lucin. 2005. Inhibition of protein kinases C prevents murine cytomegalovirus replication. J. Gen. Virol. 86:2153-2161.
27. Marschall, M., M. Freitag, S. Weiler, G. Sorg, and T. Stamminger. 2000. Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents. Antimicrob. Agents Chemother. 44:1588-1597.
28. McSharry, J. J. 2000. Analysis of virus-infected cells by flow cytometry. Methods 21:249-257.
29. Mocarski, E. S., and C. T. Courcelle. 2001. Cytomegaloviruses and their replication, p. 2629-2673. In D. M. Knipe and P. M. Howley (ed.), Fields virology. Lippincott Williams & Wilkins, Philadelphia, PA.
30. Munger, J., D. Yu, and T. Shenk. 2006. UL26-deficient human cytomegalovirus produces virions with hypophosphorylated pp28 tegument protein that is unstable within newly infected cells. J. Virol. 80:3541-3548.
31. Nozawa, N., S. Koyano, Y. Yamamoto, Y. Inami, I. Kurane, and N. Inoue. 2007. Real-time PCR assay using specimens on filter disks as a template for detection of cytomegalovirus in urine. J. Clin. Microbiol. 45:1305-1307.
32. Ogawa, H., T. Suzutani, Y. Baba, S. Koyano, N. Nozawa, K. Ishibashi, K. Fujieda, N. Inoue, and K. Omori. 2007. Etiology of severe sensorineural hearing loss in children: independent impact of congenital cytomegalovirus infection and GJB2 mutations. J. Infect. Dis. 195:782-788.
33. Ogawa-Goto, K., K. Tanaka, W. Gibson, E. Moriishi, Y. Miura, T. Kurata, S. Irie, and T. Sata. 2003. Microtubule network facilitates nuclear targeting of human cytomegalovirus capsid. J. Virol. 77:8541-8547.
34. Olivo, P. D. 1996. Transgenic cell lines for detection of animal viruses. Clin. Microbiol. Rev. 9:321-334.
35. Pass, R. F. 2001. Cytomegalovirus, p. 2675-2705. In D. M. Knipe and P. M. Howley (ed.), Fields virology. Lippincott Williams & Wilkins, Philadelphia, PA.
36. Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90:8392-8396.
37. Rybak, R. J., C. B. Hartline, Y. L. Qiu, J. Zemlicka, E. Harden, G. Marshall, J. P. Sommadossi, and E. R. Kern. 2000. In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections. Antimicrob. Agents Chemother. 44:1506-1511.
38. Sanchez, V., A. K. McElroy, J. Yen, S. Tamrakar, C. L. Clark, R. A. Schwartz, and D. H. Spector. 2004. Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production. J. Virol. 78:11219-11232.
39. Siennicka, J., A. Trzcińska, and M. Kańtoch. 2002. Evaluation of antiviral activity of different origin compounds by flow cytometry. Acta Microbiol. Pol. 51:79-83.
40. Sodeik, B., M. W. Ebersold, and A. Helenius. 1997. Microtubule-mediated transport of incoming herpes simplex virus 1 capsids to the nucleus. J. Cell Biol. 136:1007-1021.
41. Spaete, R. R., and E. S. Mocarski. 1987. Insertion and deletion mutagenesis of the human cytomegalovirus genome. Proc. Natl. Acad. Sci. USA 84:7213-7217.
42. Stránská, R., R. Schuurman, D. R. Scholl, J. A. Jollick, C. J. Shaw, C. Loef, M. Polman, and A. M. van Loon. 2004. ELVIRA HSV, a yield reduction assay for rapid herpes simplex virus susceptibility testing. Antimicrob. Agents Chemother. 48:2331-2333.
43. Straus, S. E., H. S. Aulakh, W. T. Ruyechan, J. Hay, T. A. Casey, G. F. Vande Woude, J. Owens, and H. A. Smith. 1981. Structure of varicella-zoster virus DNA. J. Virol. 40:516-525.
44. Taylor, S. L., P. R. Kinchington, A. Brooks, and J. F. Moffat. 2004. Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus. J. Virol. 78:2853-2862.
45. Ueno, T., Y. Eizuru, H. Katano, T. Kurata, T. Sata, S. Irie, and K. Ogawa-Goto. 2006. Novel real-time monitoring system for human cytomegalovirus-infected cells in vitro that uses a green fluorescent protein-PML-expressing cell line. Antimicrob. Agents Chemother. 50:2806-2813.
46. Visalli, R. J., and M. van Zeijl. 2003. DNA encapsidation as a target for anti-herpesvirus drug therapy. Antivir. Res. 59:73-87.
47. Wang, G. Q., T. Suzutani, Y. Yamamoto, Y. Fukui, N. Nozawa, D. S. Schmid, I. Kurane, and N. Inoue. 2006. Generation of a reporter cell line for detection of infectious varicella-zoster virus and its application to antiviral studies. Antimicrob. Agents Chemother. 50:3142-3145.
48. Yamamoto, N., Y. Yamada, T. Daikoku, Y. Nishiyama, Y. Tsutsui, N. Shimada, and K. Takahashi. 1990. Antiviral effect of oxetanocin G against guinea pig cytomegalovirus infection in vitro and in vivo. J. Antibiot. (Tokyo) 43:1573-1578.